TG Therapeutics, Inc. (NASDAQ:TGTX) Stake Boosted by XTX Topco Ltd

Key Points

• XTX Topco Ltd has significantly boosted its stake in TG Therapeutics by 197.8% during the first quarter, owning a total of 39,618 shares valued at approximately $1.56 million.
• Analysts have raised TG Therapeutics to a "hold" rating with a target price of $37.00, while the company has a consensus rating of "Moderate Buy" and a price target of $43.80.
• Despite a strong quarterly revenue of $120.86 million, TG Therapeutics reported an EPS of $0.03, missing analysts' expectations by $0.16.

XTX Topco Ltd grew its stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 197.8% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 39,618 shares of the biopharmaceutical company's stock after acquiring an additional 26,314 shares during the period. XTX Topco Ltd's holdings in TG Therapeutics were worth $1,562,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. NBC Securities Inc. lifted its stake in shares of TG Therapeutics by 82,300.0% in the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 823 shares during the last quarter. Golden State Wealth Management LLC lifted its stake in shares of TG Therapeutics by 100.0% in the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 433 shares during the last quarter. Vermillion Wealth Management Inc. acquired a new stake in shares of TG Therapeutics in the 4th quarter valued at $30,000. USA Financial Formulas acquired a new position in TG Therapeutics during the 1st quarter worth $57,000. Finally, Quadrant Capital Group LLC lifted its position in TG Therapeutics by 137.1% during the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after acquiring an additional 975 shares during the last quarter. 58.58% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group raised shares of TG Therapeutics to a "hold" rating and set a $37.00 target price for the company in a research report on Thursday, July 10th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $43.80.

TG Therapeutics Stock Down 2.1%

Shares of TGTX opened at $35.50 on Friday. The company has a 50-day simple moving average of $36.82 and a 200-day simple moving average of $35.98. The firm has a market capitalization of $5.64 billion, a P/E ratio of 147.92 and a beta of 1.91. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.04 and a current ratio of 4.02. TG Therapeutics, Inc. has a 52 week low of $16.65 and a 52 week high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). The company had revenue of $120.86 million for the quarter, compared to analyst estimates of $117.07 million. TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The firm's quarterly revenue was up 90.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.07) EPS. On average, equities research analysts expect that TG Therapeutics, Inc. will post 0.08 earnings per share for the current year.

Insider Activity at TG Therapeutics

In other news, Director Yann Echelard sold 10,000 shares of the company's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $36.94, for a total transaction of $369,400.00. Following the completion of the transaction, the director owned 228,816 shares of the company's stock, valued at approximately $8,452,463.04. This represents a 4.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 10.64% of the company's stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.